PMN.TO - ProMIS Neurosciences Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.355
-0.020 (-5.33%)
As of 1:10PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.375
Open0.375
Bid0.355 x 0
Ask0.360 x 0
Day's Range0.350 - 0.380
52 Week Range0.180 - 0.730
Volume232,633
Avg. Volume217,080
Market Cap87.225M
Beta-4.86
PE Ratio (TTM)N/A
EPS (TTM)-0.029
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.70
  • ACCESSWIRE6 days ago

    Today's Research Reports on Centric Health, Fennec Pharmaceuticals, ProMIS Neurosciences and Theratechnologies

    NEW YORK, NY / ACCESSWIRE / July 13, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • GlobeNewswire9 days ago

    ProMIS Neurosciences to Present Preclinical Data on Alzheimer’s Disease Therapeutic Antibody PMN310 at Alzheimer’s Association International Conference

    TORONTO and CAMBRIDGE, Mass., July 10, 2018-- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated ...

  • ProMIS Neurosciences to Present Preclinical Data on Alzheimer's Disease Therapeutic Antibody PMN310 at Alzheimer's Association International Conference
    CNW Group9 days ago

    ProMIS Neurosciences to Present Preclinical Data on Alzheimer's Disease Therapeutic Antibody PMN310 at Alzheimer's Association International Conference

    PMN310 Shows Potential for Best in Class Amyloid-Beta Oligomer Selectivity TORONTO and CAMBRIDGE, MA , July 10, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company ...

  • ACCESSWIRE20 days ago

    Research Reports on ProMIS Neurosciences Spectral Medical GeneNews and Sernova

    LONDON, UK / ACCESSWIRE / June 29, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equitiesfrom the Medical Diagnostics & Research industry: ProMIS Neurosciences, Spectral Medical, GeneNews, and Sernova. The TSX Venture Exchange gained 0.51 points, or 0.07%, to finish at 737.41. Today's stocks of interest consist of: ProMIS Neurosciences Inc. (TSX: PMN), Spectral Medical Inc. (TSX: EDT), GeneNews Ltd (TSX: GEN), and Sernova Corporation (TSXV: SVA).

  • GlobeNewswire21 days ago

    ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF) (the “Corporation”), a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the voting results of the Corporation’s annual meeting of shareholders held on June 27, 2018 in Toronto, Ontario, Canada (the “Meeting”). The Corporation is pleased to announce that all of the resolutions announced in the Management Proxy Circular and placed before the Meeting were overwhelmingly approved by the shareholders.

  • ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
    CNW Group21 days ago

    ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

    ProMIS' shareholders show overwhelming support for all resolutions TSX:PMN; OTCQB: ARFXF TORONTO and CAMBRIDGE, MA , June 28, 2018 /CNW/ - ProMIS Neurosciences, Inc. (the "Corporation"), a biotechnology ...

  • ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases
    CNW Group23 days ago

    ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases

    TORONTO and CAMBRIDGE, MA, June 26, 2018 /CNW/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of treatments for neurodegenerative diseases, announced today that numerous antibodies against two new targets in neurodegenerative diseases have entered the final stage of discovery.

  • GlobeNewswire23 days ago

    ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases

    ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of treatments for neurodegenerative diseases, announced today that numerous antibodies against two new targets in neurodegenerative diseases have entered the final stage of discovery. “ProMIS’ proprietary discovery platform consists of two stages” according to Dr. Neil Cashman, ProMIS Chief Scientific Officer.

  • Newsfile24 days ago

    ProMIS Neurosciences Inc., Treating the Root Cause of Alzheimer's, CEO Clip Video

    Vancouver, British Columbia--(Newsfile Corp. - June 25, 2018) - Dr. Elliot Goldstein, President & CEO of ProMIS Neurosciences speaks on the company's developing treatments for Alzheimer's and other neurodegenerative diseases. If you cannot view the video above, please visit:http://www.b-tv.com/promis-neurosciences-ceo-clip-90sec-3/ProMIS Neurosciences Inc. is being featured on CBC's Documentary Channel the weeks of June 25 — July 8, 2018 Monday through Friday, throughout the day and evenings.ProMIS Neurosciences Inc.: (TSX: PMN)ProMIS Neurosciences is a development stage ...

  • ProMIS Neurosciences Reminds Shareholders of June 25th Voting Cut-Off for Upcoming Annual General Meeting
    CNW Group29 days ago

    ProMIS Neurosciences Reminds Shareholders of June 25th Voting Cut-Off for Upcoming Annual General Meeting

    TORONTO and CAMBRIDGE, MA, June 20, 2018 /CNW/ - ProMIS Neurosciences Inc. (the "Corporation") (TSX:PMN.TO - News) (OTCQB:ARFXF - News) would like to remind shareholders they have until 9:00 am (Toronto Time) on Monday June 25, 2018 to vote their shares for the upcoming Annual General Meeting of shareholders to be held 9:00 am (Toronto Time) on Wednesday June 27, 2018. Shareholders are urged to carefully read the information circular in connection with the Meeting. Due to essence of time, shareholders are encouraged to vote today using the internet, telephone or facsimile.

  • ACCESSWIRElast month

    Today’s Research Reports on Fennec Pharmaceuticals, ProMIS Neurosciences, Theratechnologies and Cipher Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 13, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer's Disease
    CNW Grouplast month

    ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer's Disease

    TORONTO and CAMBRIDGE, MA, June 12, 2018 /CNW/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the initiation of producer cell line development for PMN310, its lead therapeutic antibody candidate for treatment of Alzheimer's disease (AD). Selexis, SA will carry out this critical first step in the manufacturing of antibody therapeutics using the proprietary Selexis SUREtechnology Platform™.

  • GlobeNewswirelast month

    ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer’s Disease

    ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the initiation of producer cell line development for PMN310, its lead therapeutic antibody candidate for treatment of Alzheimer’s disease (AD). Selexis, SA will carry out this critical first step in the manufacturing of antibody therapeutics using the proprietary Selexis SUREtechnology Platform™. ProMIS’ lead antibody product candidate, PMN310, is a humanized antibody that binds with high affinity and selectivity for the toxic oligomers of amyloid beta (Ab), a recognized root cause of AD.

  • GlobeNewswire2 months ago

    ProMIS Neurosciences Announces First Quarter 2018 Results

    ProMIS Neurosciences Inc. (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2018. “We are very pleased with continued progress at ProMIS”, said Executive Chairman Eugene Williams. On April 30, 2018, the Company completed a private placement of 19,306,668 common share units at a price of $0.375 per unit, for gross proceeds of approximately $7,240,000.  Each unit consisted of one common share and one-half of a common share purchase warrant.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Titan Medical, ProMIS Neurosciences, Cardiome Pharma and Valeant Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / May 8, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • GlobeNewswire3 months ago

    ProMIS Neurosciences Closes $7.2 Million Private Placement

    ProMIS Neurosciences Inc. (PMN.TO) (ARFXF) is pleased to announce that it closed yesterday a private placement of 19,306,668 Units at the price of CDN$0.375 per Unit for gross proceeds of approximately CDN$7,240,000. ProMIS will compensate finders in respect of a portion of the non-US subscribers through 7% cash fees and a total of 339,360 finder warrants having the same terms as the Unit warrants.  Noble Capital Markets, Inc., which acted as placement agent for subscribers in the United States, will receive a cash commission equal to 7% of the gross proceeds placed with its US subscribers and will be issued compensation warrants to purchase up to 215,871 common shares for a period of five years at an exercise price of CDN$0.48 per share.

  • ProMIS Neurosciences Closes $7.2 Million Private Placement
    CNW Group3 months ago

    ProMIS Neurosciences Closes $7.2 Million Private Placement

    OTCQB:ARFXF) is pleased to announce that it closed yesterday a private placement of 19,306,668 Units at the price of CDN$0.375 per Unit for gross proceeds of approximately CDN$ 7,240,000. "We are pleased to close another successful financing," said Executive Chairman Gene Williams. "This will allow us to continue moving full speed ahead with our lead program PMN310, which selectively targets the toxic oligomers of amyloid beta, a root cause of Alzheimer's disease.

  • ACCESSWIRE3 months ago

    Today's Free Reports ProMIS Neurosciences, Spectral Medical, GeneNews, and Sernova

    LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Medical Diagnostics & Research industry: ProMIS Neurosciences, ...

  • ProMIS Neurosciences Announces Publication of Peer Reviewed Scientific Paper Describing a Novel Target on Toxic Oligomers of Amyloid Beta in Alzheimer's Disease
    CNW Group3 months ago

    ProMIS Neurosciences Announces Publication of Peer Reviewed Scientific Paper Describing a Novel Target on Toxic Oligomers of Amyloid Beta in Alzheimer's Disease

    Scientific Publication Describes One of Six Distinct Therapeutic Targets on Toxic Prion-Like Amyloid Beta Oligomers TORONTO and CAMBRIDGE, MA , April 10, 2018 /CNW/ - ProMIS Neurosciences, Inc., a biotechnology ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Aphria, Titan Medical, ProMIS Neurosciences and Cardiome Pharma

    NEW YORK, NY / ACCESSWIRE / April 9, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing
    CNW Group4 months ago

    ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing

    TORONTO and CAMBRIDGE, MA, April 3, 2018 /CNW/ - ProMIS Neurosciences, a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the appointment of Ernest D. Bush to the position of Head of Pharmacology/Toxicology and Russell Blacher to the position of Head of Manufacturing.

  • ProMIS Neurosciences Appoints Dr. Sharon Cohen to Scientific Advisory Board
    PR Newswire4 months ago

    ProMIS Neurosciences Appoints Dr. Sharon Cohen to Scientific Advisory Board

    TORONTO and CAMBRIDGE, MA, March 20, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the appointment of Sharon Cohen, MD, to the Company's scientific advisory board (SAB). Dr. Cohen is the Medical Director and Principal Investigator of Toronto Memory Program, an independent medical facility for dementia care and research.